Research progress on the mechanism of Traditional Chinese Medicine regulating intestinal function in the treatment of hepatocellular carcinoma based on the gut liver axis
-
摘要: 原发性肝癌是全球发病率和病死率较高的恶性肿瘤之一，其中肝细胞癌占90%以上。肠道和肝脏通过门静脉、胆道和体循环的双向连接进行交流，肠肝轴成为肝细胞癌发病机制中的重要环节。肠道屏障功能障碍和肠道微生物失调是肝细胞癌发生的重要因素。中医药临床应用已有数千年的历史，基于肠肝轴理论，中医药防治肝细胞癌可有效阻断肠道-肝脏信号，对肝细胞癌的精准预防与治疗具有重要意义。本文在中医药脏腑理论和肠肝轴理论的基础上，总结中医药及其活性成分对肝细胞癌的调节及干预作用，希望为肝细胞癌的进一步临床防治提供新的策略和思路。Abstract: Primary liver carcinoma is one of the malignant tumors with high incidence rate and mortality in the world, of which hepatocellular carcinoma accounts for more than 90%.The intestine and liver communicate through bidirectional connections between the portal vein, bile duct, and systemic circulation, and the gut liver axis becomes an important link in the pathogenesis of hepatocellular carcinoma. Intestinal barrier dysfunction and dysbiosis of gut microbiota are important factors in the occurrence of hepatocellular carcinoma. Traditional Chinese Medicine has a history of thousands of years in clinical application. Based on the theory of the gut liver axis, Traditional Chinese Medicine can effectively block the gut liver signal in the prevention and treatment of hepatocellular carcinoma, which is of great significance for precise prevention and treatment of hepatocellular carcinoma. This article summarizes the regulatory and intervention effects of Traditional Chinese Medicine and its active ingredients on hepatocellular carcinoma based on the theory of visceral organs and the theory of gut liver axis, hoping to provide new strategies and ideas for further clinical prevention and treatment of hepatocellular carcinoma.
-
-
[1] Zhang W, Xu X, Cai L, et al. Dysbiosis of the gut microbiome in elderly patients with hepatocellular carcinoma[J]. Sci Rep, 2023, 13(1): 7797. doi: 10.1038/s41598-023-34765-w
[2] Zhou N, Mao F, Cheng S. Mechanism Research and Application for Ginsenosides in the Treatment of Hepatocellular Carcinoma[J]. Biomed Res Int, 2023, 2023: 7214037.
[3] Zhu Y, Mei Y, Baby N, et al. Tumor-mediated microbiota alteration impairs synaptic tagging/capture in the hippocampal CA1 area via IL-1β production[J]. Commun Biol, 2023, 6(1): 685. doi: 10.1038/s42003-023-05036-1
[4] Dapito DH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4[J]. Cancer Cell, 2012, 21(4): 504-516. doi: 10.1016/j.ccr.2012.02.007
[5] Zou H, Zhang M, Zhu X, et al. Ginsenoside Rb1 Improves Metabolic Disorder in High-Fat Diet-Induced Obese Mice Associated With Modulation of Gut Microbiota[J]. Front Microbiol, 2022, 13: 826487. doi: 10.3389/fmicb.2022.826487
[6] Sardana K, Sachdeva S. Role of nutritional supplements in selected dermatological disorders: A review[J]. J Cosmet Dermatol, 2022, 21(1): 85-98. doi: 10.1111/jocd.14436
[7] Jia W, Rajani C, Xu H, et al. Gut microbiota alterations are distinct for primary colorectal cancer and hepatocellular carcinoma[J]. Protein Cell, 2021, 12(5): 374-393. doi: 10.1007/s13238-020-00748-0
[8] Tsiaoussis GI, Assimakopoulos SF, Tsamandas AC, et al. Intestinal barrier dysfunction in cirrhosis: Current concepts in pathophysiology and clinical implications[J]. World J Hepatol, 2015, 7(17): 2058-2068. doi: 10.4254/wjh.v7.i17.2058
[9] 宋雪, 吕冠华, 范颖. 基于仲景"肝病实脾"理论探析现代临床肝病治法[J/OL]. 亚太传统医药, 1-5[2024-02-19].
http://kns.cnki.net/kcms/detail/42.1727.r.20231207.1639.006.html. [10] Zundler S, Günther C, Kremer AE, et al. Gut immune cell trafficking: inter-organ communication and immune-mediated inflammation[J]. Nat Rev Gastroenterol Hepatol, 2023, 20(1): 50-64. doi: 10.1038/s41575-022-00663-1
[11] Zeuzem S. Gut-liver axis[J]. Int J Colorectal Dis, 2000, 15(2): 59-82. doi: 10.1007/s003840050236
[12] Frontiers Production Office. Erratum: Modulation of Gut Microbiota by Magnesium Isoglycyrrhizinate Mediates Enhancement of Intestinal Barrier Function and Amelioration of Methotrexate-Induced Liver Injury[J]. Front Immunol, 2022, 13: 976502. doi: 10.3389/fimmu.2022.976502
[13] Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation[J]. Nat Rev Gastroenterol Hepatol, 2017, 14(9): 527-539. doi: 10.1038/nrgastro.2017.72
[14] Albillos A, DE gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy[J]. J Hepatol, 2020, 72(3): 558-577. doi: 10.1016/j.jhep.2019.10.003
[15] Fujimoto Y, Namisaki T, Takeda S, et al. Leaky Gut and Severe Adverse Events in Advanced Hepatocellular Carcinoma Treated With Lenvatinib[J]. Anticancer Res, 2022, 42(10): 4895-4905. doi: 10.21873/anticanres.15995
[16] Yoon H, Kim NE, Park J, et al. Analysis of the gut microbiome using extracellular vesicles in the urine of patients with colorectal cancer[J]. Korean J Intern Med, 2023, 38(1): 27-38. doi: 10.3904/kjim.2022.112
[17] Lin RS, Lee FY, Lee SD, et al. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation[J]. J Hepatol, 1995, 22(2): 165-172. doi: 10.1016/0168-8278(95)80424-2
[18] Fukui H, Brauner B, Bode JC, et al. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay[J]. J Hepatol, 1991, 12(2): 162-169. doi: 10.1016/0168-8278(91)90933-3
[19] Bellot P, Garcia-pagan JC, Frances R, et al. Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis[J]. Hepatology, 2010, 52(6): 2044-2052. doi: 10.1002/hep.23918
[20] Bian CF, Wang Y, Yu A, et al. Gut microbiota changes and biological mechanism in hepatocellular carcinoma after transarterial chemoembolization treatment[J]. Front Oncol, 2022, 12: 1002589. doi: 10.3389/fonc.2022.1002589
[21] Milosevic I, Vujovic A, Barac A, et al. Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature[J]. Int J Mol Sci, 2019, 20(2): 395. doi: 10.3390/ijms20020395
[22] 张翔宇, 杜娟, 李霞. 中医药通过改善细胞外基质硬度影响肝细胞癌复发转移的研究进展[J]. 中医肿瘤学杂志, 2023, 5(6): 101-107. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYZL202306016.htm
[23] 张小俊, 周朝娟, 丁斗, 等. 杨忠光主任以疏肝实脾益肾论治肝癌经验总结[J]. 光明中医, 2023, 38(21): 4136-4139. https://www.cnki.com.cn/Article/CJFDTOTAL-GMZY202321012.htm
[24] 莫世聪, 廖莹莹, 罗银冰, 等. 中医、中西医治疗原发性肝癌的研究进展[J]. 世界中西医结合杂志, 2023, 18(9): 1904-1908. https://www.cnki.com.cn/Article/CJFDTOTAL-SJZX202309037.htm
[25] 石玮, 黄春丽, 欧飞凤, 等. 原发性肝癌的中医研究进展及思考[J]. 内蒙古中医药, 2023, 42(10): 148-150. https://www.cnki.com.cn/Article/CJFDTOTAL-NZYY202310063.htm
[26] Yifu F, Hetong Z, Yani Z, et al. Effectiveness of Jiedu granule on gut microbiota in patients with advanced hepatocellular carcinoma: a randomized controlled trial[J]. J Tradit Chin Med, 2022, 42(6): 988-996.
[27] 许雅青, 吴月滢, 李小雅, 等. 健脾类中药修复肠黏膜屏障损伤的研究进展[J]. 中国实验方剂学杂志, 2021, 27(14): 235-241. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSFX202114034.htm
[28] Assimakopoulos SF, Scopa CD, Vagianos CE. Pathophysiology of increased intestinal permeability in obstructive jaundice[J]. World J Gastroenterol, 2007, 13(48): 6458-6464. doi: 10.3748/wjg.v13.i48.6458
[29] Bae SH, Park JB, Zheng YF, et al. Pharmacokinetics and tissue distribution of ginsenoside Rh2 and Rg3 epimers after oral administration of BST204, a purified ginseng dry extract, in rats[J]. Xenobiotica, 2014, 44(12): 1099-1107. doi: 10.3109/00498254.2014.929192
[30] Guo M, Zhu C, Fu R, et al. Ginsenoside Rk3 Regulates Nonalcoholic Steatohepatitis by Modulation of Intestinal Flora and the PI3K/AKT Signaling Pathway in C57BL/6 Mice[J]. J Agric Food Chem, 2023, 71(24): 9370-9380. doi: 10.1021/acs.jafc.3c00789
[31] Ren Z, Chen X, Hong L, et al. Nanoparticle Conjugation of Ginsenoside Rg3 Inhibits Hepatocellular Carcinoma Development and Metastasis[J]. Small, 2020, 16(2): e1905233. doi: 10.1002/smll.201905233
[32] Qu L, Liu Y, Deng J, et al. Ginsenoside Rk3 is a novel PI3K/AKT-targeting therapeutics agent that regulates autophagy and apoptosis in hepatocellular carcinoma[J]. J Pharm Anal, 2023, 13(5): 463-482. doi: 10.1016/j.jpha.2023.03.006
[33] 刘世锋, 董文静, 杨兰, 等. 灵芝多糖及其菌群代谢产物对HepG2细胞胰岛素抵抗的改善作用及机制[J]. 食品工业科技, 2023, 44(23): 314-321. https://www.cnki.com.cn/Article/CJFDTOTAL-SPKJ202323036.htm
[34] Chen N, Liu D, Soromou LW, et al. Paeonol suppresses lipopolysaccharide-induced inflammatory cytokines in macrophage cells and protects mice from lethal endotoxin shock[J]. Fundam Clin Pharmacol, 2014, 28(3): 268-276. doi: 10.1111/fcp.12019
[35] Chen XJ, Tang ZH, Li XW, et al. Chemical Constituents, Quality Control, and Bioactivity of Epimedii Folium(Yinyanghuo)[J]. Am J Chin Med, 2015, 43(5): 783-834. doi: 10.1142/S0192415X15500494
[36] Li Z, Zhao Y, Cheng J, et al. Integrated Plasma Metabolomics and Gut Microbiota Analysis: The Intervention Effect of Jiawei Xiaoyao San on Liver Depression and Spleen Deficiency Liver Cancer Rats[J]. Front Pharmacol, 2022, 13: 906256. doi: 10.3389/fphar.2022.906256
[37] Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular Carcinoma Is Associated With Gut Microbiota Profile and Inflammation in Nonalcoholic Fatty Liver Disease[J]. Hepatology, 2019, 69(1): 107-120. doi: 10.1002/hep.30036
[38] Xie G, Wang X, Liu P, et al. Distinctly altered gut microbiota in the progression of liver disease[J]. Oncotarget, 2016, 7(15): 19355-19366. doi: 10.18632/oncotarget.8466
[39] Wang M, Dong Y, Wu J, et al. Baicalein ameliorates ionizing radiation-induced injuries by rebalancing gut microbiota and inhibiting apoptosis[J]. Life Sci, 2020, 261: 118463. doi: 10.1016/j.lfs.2020.118463
[40] Hu Q, Zhang W, Wu Z, et al. Baicalin and the liver-gut system: Pharmacological bases explaining its therapeutic effects[J]. Pharmacol Res, 2021, 165: 105444. doi: 10.1016/j.phrs.2021.105444
[41] 王培培, 王永辉, 王丽森, 等. 华蟾素辅助顺铂化疗对H22肝癌小鼠的抑瘤作用及其相关机制研究[J]. 中国中药杂志, 2020, 45(16): 3945-3951. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGZY202016027.htm
[42] 邓向亮, 林倩倩, 罗霞, 等. 枸杞多糖对H22肝癌小鼠肠道大肠杆菌、双歧杆菌和乳酸杆菌的影响[J]. 食品科技, 2019, 44(12): 247-252. https://www.cnki.com.cn/Article/CJFDTOTAL-SSPJ201912044.htm
[43] Zhen H, Qian X, Fu X, et al. Regulation of Shaoyao Ruangan Mixture on Intestinal Flora in Mice With Primary Liver Cancer[J]. Integr Cancer Ther, 2019, 18: 1534735419843178.
[44] Xu F, Li H, Pan Y, et al. Effects of Ganfule capsule on microbial and metabolic profiles in anti-hepatocellular carcinoma[J]. J Appl Microbiol, 2022, 132(3): 2280-2292. doi: 10.1111/jam.15307
[45] Fu J, Liang Y, Shi Y, et al. HuangQi ChiFeng decoction maintains gut microbiota and bile acid homeostasis through FXR signaling to improve atherosclerosis[J]. Heliyon, 2023, 9(11): e21935. doi: 10.1016/j.heliyon.2023.e21935
-
计量
- 文章访问数: 2354
- PDF下载数: 2216
- 施引文献: 0
下载: